Enhancing Dissolution Rates of Gliclazide via Co-crystallization with Nicotinamide
Keywords:
gliclazide, nicotinamide, co-crystallization, dissolution rateAbstract
Gliclazide is a drug with poor water solubility and high permeability (BCS II), The absorption rate of this drug, when taken orally is controlled by dissolution rate in the gastrointestinal tracts. Co-crystallization method is widely used to improve the dissolution rate of this type of drug. This study aims to improve the dissolution rate of gliclazide by Co-crystallization method with nicotinamide as a coformer. Co-crystallization were prepared by solvent evaporation methods using methanol. Pure gliclazide, co-crystal gliclazide-nicotinamide in molar ratio 1:0,5, 1:1, 1:2, 1:2,5, 1:3, 1:3,5, 1:4, 1:5, and 1:7 and physical mixtures were characterized by DSC, FTIR, XRD and dissolution testing. Characterization by DSC and XRD in ratio 1:0,5, 1:1, and 1:2 showed a lower endothermic peak of gliclazide, and decrease in the intensity of the diffraction pattern by XRD. Characterization by FTIR virtually showed no shift of absorption peaks of gliclazide in ratio 1:0,5, 1:1, and 1:2. FTIR spectrum of cocrystal in ratio 1:7 showed a shift of absorption peaks for C=O and N-H. Results of dissolution testing for cocrystal in ratio 1:0,5, 1:3, 1:7, and physical mixture in ratio 1:7 showed higher dissolution rate than pure gliclazide. The highest of dissolution rate is cocrystal gliclazide-nicotinamide in ratio 1:7. Similarity analysis (f2) showed no similarity of dissolution rate for pure gliclazide, cocrystal gliclazide-nicotinamide in ratio 1:0,5, 1:3, 1:7 and physical mixture in ratio 1:7.
Â
Â
References
Abdou H. Dissolution, Bioavailability, and Bioequivalence. Pennsylvania: Mack Publishing Company; 1989. 53,72 p.
Mirza S, Heinämäki J, Miroshnyk I, Yliruusi J. L24 Co-crystals: An emerging approach to improving properties of pharmaceutical solids. Eur J Pharm Sci. 2008;34(1):S16–7.
Sekhon BS. Pharmaceutical Co-Crystals - an Update. 2009;1(2):24–39.
Saharan VA, Kukkar V, Kataria M, Gera1 M, Choudhury PK. of Health Research. Int J Heal Res. 2008;1(March):3–14.
Fda U. Guidance for Industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system. Washington DC US Dep Heal Hum Serv [Internet]. 2000;(May 2015):1–2. Available from: http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Guidance+for+Industry+Waiver+of+In+Vivo+Bioavailability+and+bioequivalence+studies#0
Davis N. Insulin, Oral Hypoglycemic Agents and The Pharmacology of The Endocrine Pancreas, in  Goodman and Gilman’s : The Pharmacological Basic of Therapeutics, 11th ed. New York: Mc Graw-Hill Inc; 2006. 1634 – 1637 p.
Sarkar A, Tiwari A, Bhasin PS, Mitra M. Pharmacological and pharmaceutical profile of gliclazide: A review. J Appl Pharm Sci. 2011;1(04):11–9.
European Directorate for Quality of Medicines & Health Care (EDQM). European Pharmacopoeia, 6th ed.vol 2. Strasbourg: Council of Europe; 2008.
Agustin R, Sari N, Zaini E. Pelepasan Ibuprofen dari Gel Karbomer 940 Co-Crystal . 2014;01(01):79–88.
Skoog DA, Holler FJ, Nieman TA. Instrumental Analysis Fifth Edition Contents Overview. Orlando: Harcourt Brace & Co; 1997;294, 380, 805 p.
Criterion P-F, Gray V. Determining Similarity of Products Variability of Dissolution Test Bioequivalence Testing , using the Dissolution Profile Bioequivalence Tool. 2010;1–26.
Downloads
Published
Issue
Section
License
Copyright © The Author(s). This article is published under the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
